

Philip E Tarr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3108080/publications.pdf>

Version: 2024-02-01

65
papers

1,975
citations

331670

21
h-index

265206

42
g-index

70
all docs

70
docs citations

70
times ranked

2586
citing authors

#	ARTICLE	IF	CITATIONS
1	The Youth Attitudes about Vaccines (YAV-5) scale: adapting the parent attitudes about childhood vaccines short scale for use with youth in German, French, and Italian in Switzerland, exploratory factor analysis and mokken scaling analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5183-5190.	3.3	5
2	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). <i>International Journal of Epidemiology</i> , 2022, 51, 33-34j.	1.9	69
3	Trust, affect, and choice in parents'™ vaccination decision-making and health-care provider selection in Switzerland. <i>Sociology of Health and Illness</i> , 2022, 44, 41-58.	2.1	21
4	Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years. <i>Journal of Infectious Diseases</i> , 2022, 225, 1581-1591.	4.0	3
5	HPV vaccine awareness, knowledge and information sources among youth in Switzerland: a mixed methods study. <i>BMJ Open</i> , 2022, 12, e054419.	1.9	11
6	Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. <i>Scientific Reports</i> , 2022, 12, 577.	3.3	27
7	Healthcare professional and professional stakeholders'™ perspectives on vaccine mandates in Switzerland: A mixed-methods study. <i>Vaccine</i> , 2022, 40, 7397-7405.	3.8	13
8	Impact of Latent Tuberculosis on Diabetes. <i>Journal of Infectious Diseases</i> , 2022, 225, 2229-2234.	4.0	3
9	Parents'™ vaccination information seeking, satisfaction with and trust in medical providers in Switzerland: a mixed-methods study. <i>BMJ Open</i> , 2022, 12, e053267.	1.9	14
10	Vaccine hesitancy and HPV vaccine uptake among male and female youth in Switzerland: a cross-sectional study. <i>BMJ Open</i> , 2022, 12, e053754.	1.9	6
11	Parental and provider vaccine hesitancy and non-timely childhood vaccination in Switzerland. <i>Vaccine</i> , 2022, 40, 3193-3202.	3.8	10
12	Telomere Length, Traditional Risk Factors, Factors Related to Human Immunodeficiency Virus (HIV) and Coronary Artery Disease Events in Swiss Persons Living With HIV. <i>Clinical Infectious Diseases</i> , 2021, 73, e2070-e2076.	5.8	7
13	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV. <i>Annals of Internal Medicine</i> , 2021, 174, 758-767.	3.9	66
14	Application of the Parent Attitudes about Childhood Vaccines (PACV) survey in three national languages in Switzerland: Exploratory factor analysis and Mokken scale analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2652-2660.	3.3	16
15	Alcohol consumption and neurocognitive deficits in people with well-treated HIV in Switzerland. <i>PLoS ONE</i> , 2021, 16, e0246579.	2.5	3
16	Impact of Delaying Antiretroviral Treatment During Primary Human Immunodeficiency Virus Infection on Telomere Length. <i>Journal of Infectious Diseases</i> , 2021, , .	4.0	2
17	Coronary Artery Disease-Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1597-1604.	5.8	5
18	Neurocognitive course at two-year follow-up in the neurocognitive assessment in the metabolic and aging cohort (NAMACO) study. <i>Aids</i> , 2021, Publish Ahead of Print, 2469-2480.	2.2	6

#	ARTICLE	IF	CITATIONS
19	Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 758-764.	3.0	14
20	“Vaccination needs to be easy for the people, right?” a qualitative study of the roles of physicians and pharmacists regarding vaccination in Switzerland. <i>BMJ Open</i> , 2021, 11, e053163.	1.9	5
21	Self-reported Neurocognitive Impairment in People Living With Human Immunodeficiency Virus (HIV): Characterizing Clusters of Patients With Similar Changes in Self-reported Neurocognitive Impairment, 2013–2017, in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 637-644.	5.8	3
22	Longitudinal Progression of Subclinical Coronary Atherosclerosis in Swiss HIV-Positive Compared With HIV-Negative Persons Undergoing Coronary Calcium Score Scan and CT Angiography. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa438.	0.9	4
23	Intra-Abdominal Nocardiosis—Case Report and Review of the Literature. <i>Journal of Clinical Medicine</i> , 2020, 9, 2141.	2.4	10
24	Rapid Progression of Kidney Dysfunction in People Living With HIV: Use of Polygenic and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Risk Scores. <i>Journal of Infectious Diseases</i> , 2020, 223, 2145-2153.	4.0	7
25	Recurrent <i>Campylobacter</i> Enteritis in Patients with Hypogammaglobulinemia: Review of the Literature. <i>Journal of Clinical Medicine</i> , 2020, 9, 553.	2.4	10
26	Collaborating with Complementary and Alternative Medicine (CAM) Providers When Writing HPV Vaccine Review Articles. <i>Journal of Clinical Medicine</i> , 2020, 9, 592.	2.4	5
27	Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz464.	0.9	7
28	“Problem patients and physicians’ failures”: What it means for doctors to counsel vaccine hesitant patients in Switzerland. <i>Social Science and Medicine</i> , 2020, 255, 112946.	3.8	24
29	Subclinical Atherosclerosis Imaging in People Living with HIV. <i>Journal of Clinical Medicine</i> , 2019, 8, 1125.	2.4	9
30	“We treat humans, not herds!” A qualitative study of complementary and alternative medicine (CAM) providers’ individualized approaches to vaccination in Switzerland. <i>Social Science and Medicine</i> , 2019, 240, 112556.	3.8	38
31	The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2019, 24, 343-353.	1.0	4
32	Antiretroviral Drugs Associated With Subclinical Coronary Artery Disease in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 70, 884-889.	5.8	11
33	Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate. <i>Clinical Infectious Diseases</i> , 2019, 70, 890-897.	5.8	7
34	Psoas Abscess Due to <i>Mycobacterium avium</i> in A Patient with Chronic Lymphocytic Leukemia—Case Report and Review. <i>Journal of Clinical Medicine</i> , 2019, 8, 216.	2.4	7
35	Determinants of vaccine hesitancy in Switzerland: study protocol of a mixed-methods national research programme. <i>BMJ Open</i> , 2019, 9, e032218.	1.9	44
36	Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz277.	0.9	20

#	ARTICLE	IF	CITATIONS
37	Measles in Switzerland – progress made, but communication challenges lie ahead. <i>Swiss Medical Weekly</i> , 2019, 149, w20105.	1.6	7
38	Will NNRTIs be driving forward again?. <i>Lancet HIV</i> , 2018, 5, e200-e201.	4.7	5
39	Dietary Patterns and Physical Activity Correlate With Total Cholesterol Independently of Lipid-Lowering Drugs and Antiretroviral Therapy in Aging People Living With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy067.	0.9	12
40	Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons. <i>European Heart Journal</i> , 2018, 39, 2147-2154.	2.2	47
41	Systematic De-escalation of Successful Triple Antiretroviral Therapy to Dual Therapy with Dolutegravir plus Emtricitabine or Lamivudine in Swiss HIV-positive Persons. <i>EClinicalMedicine</i> , 2018, 6, 21-25.	7.1	15
42	Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma. <i>Aids</i> , 2018, 32, 2759-2765.	2.2	6
43	Anti-inflammatory therapy in well controlled HIV infection. <i>Lancet HIV</i> , 2018, 5, e538-e539.	4.7	4
44	Incidental Findings on Coronary Computed Tomography Angiography in Human Immunodeficiency Virus (HIV)-Positive and HIV-Negative Persons. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy084.	0.9	3
45	HIV and Aging – Perhaps Not as Dramatic as We Feared?. <i>Gerontology</i> , 2018, 64, 446-456.	2.8	7
46	Another statin option in HIV. <i>Lancet HIV</i> , 2017, 4, e278-e279.	4.7	0
47	Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx177.	0.9	10
48	Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia. <i>European Respiratory Journal</i> , 2016, 48, 1150-1159.	6.7	43
49	Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv108.	0.9	38
50	Reasons for late presentation to HIV care in Switzerland. <i>Journal of the International AIDS Society</i> , 2015, 18, 20317.	3.0	52
51	Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet</i> , 2015, 385, 1511-1518.	13.7	326
52	Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu040.	0.9	61
53	Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. <i>Clinical Infectious Diseases</i> , 2013, 57, 112-121.	5.8	56
54	Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics. <i>Pharmacogenomics</i> , 2010, 11, 587-594.	1.3	22

#	ARTICLE	IF	CITATIONS
55	Impact of Single Nucleotide Polymorphisms and of Clinical Risk Factors on New-Onset Diabetes Mellitus in HIV-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2010, 51, 1090-1098.	5.8	26
56	Genetic screening for metabolic and age-related complications in HIV-infected persons. <i>F1000 Medicine Reports</i> , 2010, 2, 83.	2.9	8
57	Contribution of Genome-Wide Significant Single-Nucleotide Polymorphisms and Antiretroviral Therapy to Dyslipidemia in HIV-Infected Individuals. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 621-628.	5.1	38
58	High Prevalence of Peripheral Arterial Disease in HIV-Infected Persons. <i>Clinical Infectious Diseases</i> , 2008, 46, 761-767.	5.8	105
59	Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 755-764.	1.5	74
60	Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications. <i>Antiviral Therapy</i> , 2007, 12, 999-1013.	1.0	7
61	Toxicogenetics of Antiretroviral Therapy: Genetic Factors that Contribute to Metabolic Complications. <i>Antiviral Therapy</i> , 2007, 12, 999-1014.	1.0	30
62	Eligibility for and Outcome of Hepatitis C Treatment of HIV-Coinfected Individuals in Clinical Practice: The Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2006, 11, 131-142.	1.0	35
63	Modeling the Influence of APOC3, APOE, and TNF Polymorphisms on the Risk of Antiretroviral Therapy-Associated Lipid Disorders. <i>Journal of Infectious Diseases</i> , 2005, 191, 1419-1426.	4.0	105
64	Lipid Profiles for Antiretroviral-Naive Patients Starting Pi- and Nnrti-Based Therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2005, 10, 585-591.	1.0	95
65	Infections in Patients with Immunodeficiency with Thymoma (Good Syndrome). <i>Medicine (United States)</i> , 2005, 84, 1073-1078.	1.0	211